Oscar Health shares are up in a pre-earnings move as traders position ahead of the company’s upcoming Q1 2026 results, due May 6, 2026 before the market opens, with a management call scheduled for 8:00 a.m. ET. The setup is drawing incremental buying interest after Oscar’s earlier 2026 outlook reset expectations toward a profitability pivot, making the stock sensitive to any near-term read-through on medical costs and enrollment.

The next clear catalyst is the May 6 print, where consensus expectations cited in market previews call for roughly $4.91 billion in revenue and about $1.21 in EPS for the quarter. With the stock already up materially into late April, the near-term move looks less like a single headline and more like a positioning-driven bid into a binary event that can quickly reprice the name either way. (marketbeat.com)

Sentiment has also been supported by attention on CEO Mark T. Bertolini’s purchase of 1,000,000 shares at $11.92 per share in early April, a transaction disclosed in the company’s proxy materials. While insider buying doesn’t guarantee near-term performance, it can matter in a high-volatility turnaround story because it reduces perceived downside skepticism into upcoming results. (stocktitan.net)

Key swing factors for the earnings report include medical loss ratio performance, any updates to full-year 2026 guidance, and commentary on retention and risk mix in the individual ACA marketplace. If management reiterates its 2026 revenue and operating earnings trajectory, momentum traders may stick with the move; if medical-cost pressure resurfaces, the stock can retrace quickly given its history of sharp post-news swings.